Acrivon Therapeutics to Present at the Oppenheimer 32nd Annual Healthcare Conference
WATERTOWN, Massachusetts, March 16, 2022 – Acrivon Therapeutics, Inc., a clinical-stage oncology therapeutics company with proprietary technologies driving a new era of precision-based medicine, today announced that Peter Blume-Jensen, M.D., Ph.D., Acrivon’s chief executive officer and founder, will present at the Oppenheimer 32nd Annual Healthcare Conference on Thursday, March 17, 2022 at 9:20 a.m. ET.
To access the live webcast or archived recording of the presentation, please click here.
Acrivon is a clinical stage oncology company leveraging its unique, proprietary phosphoproteomics technology called Acrivon Precision Predictive Proteomics, or AP3, in development of its pipeline of oncology drugs. The AP3 platform enables the creation of drug-specific proprietary OncoSignature® companion diagnostics that can be used to identify patients most likely to benefit from Acrivon’s medicines. Through its highly specific patient selection, the company seeks to accelerate clinical development and increase the probability of successful treatment outcome for patients. The company’s pipeline includes the clinically advanced lead program, ACR-368 (also known as prexasertib), a targeted oncology asset in-licensed from Eli Lilly and Company which has demonstrated evidence of durable responses, in solid cancers in Phase 2 trials. Acrivon is also developing additional pipeline programs targeting critical nodes in DNA Damage Response (DDR) and cell cycle regulation. Please visit the company’s website at https://acrivon.com for more information.